Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study

NCT05929768 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.

NCT NCT05929768
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05929768 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study
Lead sponsor
SWOG Cancer Research Network
Phase
Phase 3
Overall status
Recruiting
Start date
September 15, 2023
Completion date
April 30, 2033
Enrollment
2,400 (estimated)
Sites
963

Conditions

As the registry lists them; a condition with its own page is linked.

anatomic stage i breast cancer ajcc v8, anatomic stage ii breast cancer ajcc v8, anatomic stage iiia breast cancer ajcc v8, anatomic stage iiib breast cancer ajcc v8, early stage triple-negative breast carcinoma